A detailed history of Eaton Vance Management transactions in United Therapeutics Corp stock. As of the latest transaction made, Eaton Vance Management holds 17,715 shares of UTHR stock, worth $6.35 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
17,715
Previous 17,688 0.15%
Holding current value
$6.35 Million
Previous $4.17 Million 11.01%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$203.3 - $244.17 $5,489 - $6,592
27 Added 0.15%
17,715 $3.71 Million
Q2 2022

Aug 15, 2022

SELL
$174.81 - $241.14 $238,615 - $329,156
-1,365 Reduced 7.16%
17,688 $4.17 Million
Q1 2022

May 16, 2022

BUY
$166.16 - $213.96 $3.06 Million - $3.94 Million
18,428 Added 2948.48%
19,053 $3.42 Million
Q4 2021

Feb 14, 2022

SELL
$184.32 - $216.08 $184 - $216
-1 Reduced 0.16%
625 $0
Q3 2021

Nov 15, 2021

SELL
$179.86 - $214.88 $97,304 - $116,250
-541 Reduced 46.36%
626 $0
Q2 2021

Aug 16, 2021

BUY
$170.47 - $211.93 $168,765 - $209,810
990 Added 559.32%
1,167 $210,000
Q1 2021

May 17, 2021

SELL
$153.94 - $174.85 $302,030 - $343,055
-1,962 Reduced 91.73%
177 $30,000
Q1 2019

May 14, 2019

SELL
$107.15 - $126.84 $13,393 - $15,855
-125 Reduced 5.52%
2,139 $251,000
Q4 2018

Feb 07, 2019

SELL
$101.4 - $128.73 $57,595 - $73,118
-568 Reduced 20.06%
2,264 $247,000
Q3 2018

Nov 13, 2018

SELL
$113.81 - $129.46 $32,435 - $36,896
-285 Reduced 9.14%
2,832 $362,000
Q2 2018

Aug 10, 2018

SELL
$101.14 - $118.31 $2,326 - $2,721
-23 Reduced 0.73%
3,117 $353,000
Q1 2018

May 07, 2018

SELL
$107.21 - $151.94 $83,945 - $118,969
-783 Reduced 19.96%
3,140 $353,000
Q4 2017

Feb 12, 2018

SELL
$118.58 - $151.28 $28,222 - $36,004
-238 Reduced 5.72%
3,923 $580,000
Q3 2017

Nov 13, 2017

BUY
$114.6 - $136.81 $476,850 - $569,266
4,161
4,161 $488,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.3B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Eaton Vance Management Portfolio

Follow Eaton Vance Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.